![]() TUB 10 months ago Estimated | Other | €0.68 Per Share |
![]() TUB 10 months ago | Other | €0.68 Per Share |
![]() TUB 3 May 2023 | Other | €0.6 Per Share |
![]() TUB 3 May 2022 | Other | €0.53 Per Share |
![]() TUB 4 May 2021 | Other | €0.48 Per Share |
![]() TUB 6 May 2020 | Other | €0.43 Per Share |
25 Apr 2025 (29 Days) Date | | - Cons. EPS | - EPS |
22 Mar 2025 Date | | - Cons. EPS | - EPS |
28 Jul 2024 Date | | - Cons. EPS | - EPS |
25 Jul 2024 Date | | - Cons. EPS | - EPS |
23 May 2024 Date | | - Cons. EPS | - EPS |
![]() TUB 10 months ago Estimated | Other | €0.68 Per Share |
![]() TUB 10 months ago | Other | €0.68 Per Share |
![]() TUB 3 May 2023 | Other | €0.6 Per Share |
![]() TUB 3 May 2022 | Other | €0.53 Per Share |
![]() TUB 4 May 2021 | Other | €0.48 Per Share |
![]() TUB 6 May 2020 | Other | €0.43 Per Share |
25 Apr 2025 (29 Days) Date | | - Cons. EPS | - EPS |
22 Mar 2025 Date | | - Cons. EPS | - EPS |
28 Jul 2024 Date | | - Cons. EPS | - EPS |
25 Jul 2024 Date | | - Cons. EPS | - EPS |
23 May 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Eric Nys CEO | XDUS Exchange | BE0003823409 ISIN |
BE Country | - Employees | 30 Apr 2024 Last Dividend | 17 Jun 2005 Last Split | - IPO Date |
Financière de Tubize SA operates as a mono holding company primarily focused on the biopharmaceutical sector, through its significant investment in UCB, a leading biopharma company based in Belgium. This strategic position allows Financière de Tubize SA to leverage the innovations and financial performance of UCB, aiming for sustained growth and value creation in the biopharmaceutical industry. The company's operational and strategic base in Brussels, Belgium, places it at the heart of Europe's biopharmaceutical hub, enabling close collaboration and strategic alignment with UCB.
The principal product and service offering of Financière de Tubize SA is centered around its investment portfolio, with a key focus on: